RAPT Therapeutics
Biotechnology ResearchView the employees at
RAPT Therapeutics-
Mikhail Zibinsky Director at RAPT Therapeutics
-
Redwood City, California, United States
-
Top 5%
Dominique CESSY Secrétaire entreprise chez Rapt-
Noisy-le-Grand, Île-de-France, France
-
Top 10%
Gwen Carscadden Chief Human Resources at RAPT Therapeutics-
San Francisco Bay Area
-
Top 5%
Sophie Bennett CARAT worker at RAPt-
London, England, United Kingdom
-
Rising Star
Parcharee Tivitmahaisoon Synthetic Organic / Medicinal Chemist-
San Francisco, California, United States
-
Top 10%
Overview
RAPT Therapeutics is a clinical stage immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The company is also pursuing a range of targets that are in the discovery stage of development.
-